Spero Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $64.92M
- P/E (TTM)
- 28.0
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | During market hours | – | $-0.16 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | $300.00K | $-0.13 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | $41.30M | $0.53 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $5.40M | $-0.13 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | $14.20M | $-0.03 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | $5.90M | $-0.25 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | During market hours | $15.00M | $-0.38 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 29, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 5, 2024 | Before market open | – | – | – |
Press releases
Announcements Spero Therapeutics filed with the SEC
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spero Therapeutics Announces $105 Million Non-Recourse
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
“forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and prospects for the Company; the ability to successfully achieve and
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward-looking Statement This presentation contains forward-looking
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
treated by tebipenem HBr and market demand for tebipenem HBr generally; the potential regulatory path forward for tebipenem HBr, the potential approval of tebipenem HBr by the U.S. Food and Drug Administration (FDA) and the timing
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Spero Therapeutics and GSK Announce PIVOT-PO phase 3 study for tebipenem HBr stopped early for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Act of 1995, as amended, including without limitation, statements regarding, among other things, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; the potential regulatory path
Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Results of operations · Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Spero Therapeutics Announces Third Quarter 2024 Operating Results
Results of operations · EX-99.1 to Form 8-K
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
Results of operations · Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
who could be treated by SPR 720 and tebipenem HBr and market demand for SPR720 and tebipenem HBr generally; the potential regulatory path forward for tebipenem HBr, the potential approval of tebipenem HBr by the U.S. Food and Drug
Results of operations · Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Forward-looking Statement This presentation contains forward-looking
Regulation FD disclosure · EX-99.1 to Form 8-K
Spero Therapeutics Announces Second Quarter 2024 Operating Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward-looking Statement This presentation contains forward-looking
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Spero Therapeutics Announces Fourth Quarter and Full Year 2023
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation January 8, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Spero Therapeutics Provides Corporate Update and 2024 Outlook
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
the U.S. Food and Drug Administration (FDA) and the timing thereof; the potential commercialization of tebipenem HBr and its future value, the potential receipt of milestone payments and royalties on future sales of tebipenem HBr under the
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Spero Therapeutics Announces First Patient First Visit for Phase 3 PIVOT-PO Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and
Executive or director change · Other events · EX-99.1 to Form 8-K
Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update
Results of operations · EX-99.1 to Form 8-K
Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a
Results of operations · EX-99.1 to Form 8-K
Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating
Results of operations · EX-99.1 to Form 8-K
the U.S. Food and Drug Administration (FDA) and the timing thereof; the potential commercialization of tebipenem HBr and its future value, the potential receipt of milestone payments, and royalties on future sales of tebipenem HBr under the
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Spero Therapeutics, Inc. A Leader in
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Spero Therapeutics Announces Third Quarter 2022 Operating Results and
Results of operations · EX-99.1 to Form 8-K
Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr
Other events · EX-99.1 to Form 8-K
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K